PE20000065A1 - Combinaciones de inhibidor de ace-inhibidor de mmp - Google Patents

Combinaciones de inhibidor de ace-inhibidor de mmp

Info

Publication number
PE20000065A1
PE20000065A1 PE1998001267A PE00126798A PE20000065A1 PE 20000065 A1 PE20000065 A1 PE 20000065A1 PE 1998001267 A PE1998001267 A PE 1998001267A PE 00126798 A PE00126798 A PE 00126798A PE 20000065 A1 PE20000065 A1 PE 20000065A1
Authority
PE
Peru
Prior art keywords
inhibitor
cardiac valve
tempylapril
ace
valve flexibility
Prior art date
Application number
PE1998001267A
Other languages
English (en)
Inventor
Joseph Thomas Peterson
Milton Lethan Pressler
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22083543&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20000065(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of PE20000065A1 publication Critical patent/PE20000065A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE a)UN INHIBIDOR DE ENZIMA CONVERTIDORA DE ANGIOTENSINA (ACE) TAL COMO CAPTOPRIL, ENALAPRIL, ENALPRILAT, LISINOPRIL, RAMIPRIL, ZOFENOPRIL, TRANDOLAPRIL, TEMOCAPRIL, CERANAPIL, ALACEPRIL, DELAPRIL, PENTOPRIL, QUINAPRIL, QUINAPRILAT, MOEXIPRIL, RENTIAPRIL, DUINAPRIL, SPIRAPRIL, CILAZAPRIL, PERINDOPRIL, FOSINOPRIL; b)UN INHIBIDOR DE METALOPROTEASA DE MATRIZ TAL COMO 4-(4`-CLOROBIFENIL-4-IL)-4-HIDROXIMINO-BUTIRICO, ACIDO 2-(4'-BROMOBIFENIL-4-SULFONILAMINO)-3- METIL-BUTIRICO O UN COMPUESTO DE FORMULA I, DONDE A ES FENILO, GRUPO a; Y ES CH o N; R1 ES ALQUILO, ARILO, HALO, AMINO OPCIONALMENTE SUSTITUIDO, ALCOXI; R2 ES CARBOXIALQUILCETONA U OXIMA, CARBOXIALQUILSULFONAMIDA. LA COMPOSICION TIENE EFECTO DE RETARDAR Y REVERTIR EL PROCESO DE FIBROSIS, DILATACION VENTRICULAR, INSUFICIENCIA CARDIACA Y PUEDE SER UTIL PARA EL TRATAMIENTO DE FIBROSIS CARDIOVASCULAR, CARDIOMIOPATIA DILATADA, ESCLEROSIS DE VALVULAS CARDIACAS, FIBROSIS DE VALVULAS CARDIACAS, ENFERMEDAD CARDIACA REUMATICA, TRASTORNOS ARTERIOSCLEROTICOS, FIBROSIS PULMONAR, SINDROME DE FATIGA RESPIRATORIA DE ADULTOS, TRASTORNOS INFLAMATORIOS, ESPONDILITIS ANQUILOSANTE, GLOMERULO ESCLEROSIS, ADHERENCIAS DEL PERITONEO
PE1998001267A 1997-12-23 1998-12-22 Combinaciones de inhibidor de ace-inhibidor de mmp PE20000065A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6859497P 1997-12-23 1997-12-23

Publications (1)

Publication Number Publication Date
PE20000065A1 true PE20000065A1 (es) 2000-02-11

Family

ID=22083543

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1998001267A PE20000065A1 (es) 1997-12-23 1998-12-22 Combinaciones de inhibidor de ace-inhibidor de mmp

Country Status (24)

Country Link
US (1) US6133304A (es)
EP (1) EP1047450B1 (es)
JP (1) JP2001526245A (es)
KR (1) KR20010033473A (es)
AR (1) AR015504A1 (es)
AT (1) ATE225187T1 (es)
AU (1) AU751701B2 (es)
BR (1) BR9814422A (es)
CA (1) CA2305436A1 (es)
CO (1) CO4970775A1 (es)
DE (1) DE69808518T2 (es)
DK (1) DK1047450T3 (es)
ES (1) ES2184340T3 (es)
HU (1) HUP0100427A3 (es)
IL (1) IL135428A0 (es)
IS (1) IS5446A (es)
NO (1) NO20003256D0 (es)
NZ (1) NZ503962A (es)
PE (1) PE20000065A1 (es)
PL (1) PL341335A1 (es)
PT (1) PT1047450E (es)
UY (1) UY25321A1 (es)
WO (1) WO1999032150A1 (es)
ZA (1) ZA9811794B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ513830A (en) * 1999-03-03 2001-09-28 Procter & Gamble Dihetero-substituted metalloprotease inhibitors
US6376524B1 (en) 2000-06-21 2002-04-23 Sunesis Pharmaceuticals, Inc. Triphenyl compounds as interleukin-4 antagonists
GB0100761D0 (en) 2001-01-11 2001-02-21 Biocompatibles Ltd Drug delivery from stents
JP4615826B2 (ja) 2001-01-29 2011-01-19 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 置換インドールおよびインテグリンアンタゴニストとしてのそれらの使用
DE10125882B4 (de) * 2001-05-28 2007-03-29 Esparma Gmbh Arzneimittel enthaltend Ambroxol, dessen Salze und/oder Prodrugs zusammen mit α-Liponsäure im Rahmen der Behandlung des Diabetes mellitus
WO2003015762A1 (fr) * 2001-08-20 2003-02-27 Ono Pharmaceutical Co., Ltd. Agent therapeutique pour insuffisance cardiaque
US7071211B2 (en) * 2002-09-27 2006-07-04 Bausch & Lomb Inc. Small organic molecules that increase the activity of gelatinase a in ocular cells
EP1545287B1 (en) * 2002-10-04 2012-12-05 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE DEPARTMENT OF HEALTH & HUMAN SERVICES Vasoregulating compounds and methods of their use
EP1575511A4 (en) * 2002-11-07 2006-06-28 Us Gov Health & Human Serv NEW TARGET FOR ANGIOGENESIS AND ANTI-ANGIOGENESIS THERAPY
WO2004060346A2 (en) 2002-12-30 2004-07-22 Angiotech International Ag Drug delivery from rapid gelling polymer composition
CA2534352A1 (en) * 2003-08-08 2005-02-17 Arriva Pharmaceuticals, Inc. Methods of protein production in yeast
JP2007511539A (ja) * 2003-11-14 2007-05-10 バクスター・インターナショナル・インコーポレイテッド α１−抗トリプシン組成物およびこのような組成物を用いた処置方法
US7914771B2 (en) * 2004-03-09 2011-03-29 Arriva Pharmaceuticals, Inc. Treatment of chronic obstructive pulmonary disease by low dose inhalation of protease inhibitor
EP1796681A2 (en) * 2004-08-02 2007-06-20 Genmedica Therapeutics SL Compounds for inhibiting copper-containing amine oxidases and uses thereof
CN100367956C (zh) * 2006-08-29 2008-02-13 陈俊云 用于治疗高血压的药物
CA2728766A1 (en) * 2008-06-20 2009-12-23 Kinemed, Inc. Compositions for the treatment of fibrotic diseases or conditions
US20110230428A1 (en) * 2008-07-22 2011-09-22 John Wityak Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
WO2011041545A1 (en) * 2009-10-01 2011-04-07 Symphony Evolution, Inc. Methods of treating aneurysmal dilatation, blood vessel wall weakness and specifically abdominal aortic and thoracic aneurysm using matrix metalloprotease-2 inhibitors
BR112014004741B1 (pt) 2011-08-30 2021-10-13 Chdi Foundation, Inc Entidade química, seu uso e composição farmacêutica compreendendo a mesma
WO2013033068A1 (en) 2011-08-30 2013-03-07 Stephen Martin Courtney Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
CA2916497C (en) 2013-06-26 2022-07-12 Stealth Biotherapeutics Corp Methods for the regulation of matrix metalloproteinase expression
MX2017000779A (es) 2014-07-17 2017-07-27 Chdi Foundation Inc Metodos y composiciones para el tratamiento de trastornos relacionados con el vih.
US20190008828A1 (en) 2015-12-28 2019-01-10 The U.S.A., As Represented By The Secretary Department Of Health And Human Services Methods for inhibiting human immunodeficiency virus (hiv) release from infected cells

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9106438A (pt) * 1990-05-11 1993-05-18 Pfizer Composicoes terapeuticas sinergisticas e processos
EP1136078A3 (en) * 1995-02-10 2002-07-24 G.D. Searle & Co. Combination of angiotensin converting enzyme inhibitor and side- effect-reduced amount of aldosterone antagonist
IL126832A0 (en) * 1996-05-17 1999-08-17 Warner Lambert Co Biphenylsulfonamide matrix metalloproteinase inhibitors
US5756545A (en) * 1997-04-21 1998-05-26 Warner-Lambert Company Biphenysulfonamide matrix metal alloproteinase inhibitors

Also Published As

Publication number Publication date
KR20010033473A (ko) 2001-04-25
HUP0100427A2 (hu) 2001-06-28
IL135428A0 (en) 2001-05-20
NZ503962A (en) 2002-03-28
HUP0100427A3 (en) 2002-11-28
DE69808518T2 (de) 2003-06-26
ES2184340T3 (es) 2003-04-01
DE69808518D1 (de) 2002-11-07
PL341335A1 (en) 2001-04-09
CO4970775A1 (es) 2000-11-07
AR015504A1 (es) 2001-05-02
WO1999032150A1 (en) 1999-07-01
PT1047450E (pt) 2003-02-28
NO20003256L (no) 2000-06-22
EP1047450B1 (en) 2002-10-02
EP1047450A1 (en) 2000-11-02
ZA9811794B (en) 1999-06-29
NO20003256D0 (no) 2000-06-22
ATE225187T1 (de) 2002-10-15
AU1522099A (en) 1999-07-12
IS5446A (is) 2000-04-14
US6133304A (en) 2000-10-17
AU751701B2 (en) 2002-08-22
DK1047450T3 (da) 2003-01-27
UY25321A1 (es) 2004-07-30
CA2305436A1 (en) 1999-07-01
BR9814422A (pt) 2000-10-10
JP2001526245A (ja) 2001-12-18

Similar Documents

Publication Publication Date Title
PE20000065A1 (es) Combinaciones de inhibidor de ace-inhibidor de mmp
Braun et al. Furin‐mediated protein processing in infectious diseases and cancer
JW Fenton et al. Thrombin structure and function: why thrombin is the primary target for antithrombotics
WO2001019788A3 (en) BENZAMIDES AND RELATED INHIBITORS OF FACTOR Xa
ME00181B (me) Farmaceutske formulacije inhibitora renin-angiotenzin sistema (ras) i njihova primjena
Slaughter et al. Antifibrinolytic drugs and perioperative hemostasis
Yamawaki-Ogata et al. Mesenchymal stem cells for treatment of aortic aneurysms
RU2001126526A (ru) Лекарственное средство, предназначенное для лечения диабета
NO973627L (no) Multifunkjonelt enzym
KR900701748A (ko) 심장혈관 장애의 치료 및 진통제로서 유용한 머캅토-아실 아미노산
Stack et al. Modulation of plasminogen activation and type IV collagenase activity by a synthetic peptide derived from the laminin A chain
Arthur Matrix degradation in liver: a role in injury and repair
Qi et al. Biomarkers in VSMC phenotypic modulation and vascular remodeling
CA2476538A1 (en) Use of erythropoietin for the preventive or curative treatment of cardiac failure
Schönherr et al. Matrix metalloproteinase expression by endothelial cells in collagen lattices changes during co‐culture with fibroblasts and upon induction of decorin expression
EA200501058A1 (ru) Фармацевтическая комбинация из телмисартана и аторвастатина для профилактики или терапевтического лечения сердечно-сосудистых, сердечно-легочных, легочных или почечных заболеваний
DE69429816D1 (de) C1-Esterasehemmer zur Verringerung von Myokardschäden bei akutem Herzinfarkt
RU2000102888A (ru) Фармацевтические композиции, включающие ингибитор альдегидредуктазы и ингибитор асе
MX9704128A (es) Sales de esteres etilicos de acidos 3-(2-(4-(4-(amino-imino-metil)-fenil)-4-metil-2,5-dioxo-imid azolidin1-il)-acetilamino)-3-fenil-propionicos.
DK169686B1 (da) Fremgangsmåde til fremstilling af en plasminogenaktivator afledt fra humannyre
Koslowski et al. Proteinases and proteinase inhibitors during the development of pulmonary fibrosis in rat
KR890701136A (ko) Ace 억제제의 혈압강하 효과의 강화방법
Pauschinger et al. Inflammation and extracellular matrix protein metabolism: two sides of myocardial remodelling
CA2397244A1 (en) Ace inhibitor-vasopressin antagonist combinations
Tyagi et al. Metalloproteinase in myocardial adaptation and maladaptation

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed